Atria Investments Inc Acquires 736 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Atria Investments Inc raised its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 14.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,724 shares of the company’s stock after acquiring an additional 736 shares during the quarter. Atria Investments Inc’s holdings in HCA Healthcare were worth $2,326,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HCA. Vanguard Group Inc. grew its stake in HCA Healthcare by 0.4% in the first quarter. Vanguard Group Inc. now owns 16,989,683 shares of the company’s stock valued at $5,666,569,000 after purchasing an additional 60,304 shares in the last quarter. Capital World Investors increased its holdings in HCA Healthcare by 57.5% during the first quarter. Capital World Investors now owns 2,792,377 shares of the company’s stock worth $931,342,000 after buying an additional 1,019,750 shares during the last quarter. Darsana Capital Partners LP grew its position in shares of HCA Healthcare by 53.3% in the 2nd quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company’s stock valued at $369,472,000 after acquiring an additional 400,000 shares during the period. TD Asset Management Inc raised its holdings in shares of HCA Healthcare by 2.7% in the 2nd quarter. TD Asset Management Inc now owns 741,130 shares of the company’s stock valued at $238,110,000 after purchasing an additional 19,812 shares during the period. Finally, Epoch Investment Partners Inc. increased its position in HCA Healthcare by 16.4% during the second quarter. Epoch Investment Partners Inc. now owns 631,854 shares of the company’s stock worth $203,002,000 after buying an additional 88,948 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the sale, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 21.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,155 shares of company stock valued at $5,608,990. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Truist Financial boosted their target price on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Morgan Stanley assumed coverage on shares of HCA Healthcare in a research report on Tuesday, September 3rd. They issued an “equal weight” rating and a $427.00 price objective on the stock. UBS Group increased their price target on shares of HCA Healthcare from $405.00 to $438.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. TD Cowen decreased their target price on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Finally, Royal Bank of Canada boosted their price target on HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $385.00.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $345.36 on Friday. The company’s 50 day simple moving average is $387.05 and its 200 day simple moving average is $357.11. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. HCA Healthcare, Inc. has a 1 year low of $237.57 and a 1 year high of $417.14. The stock has a market capitalization of $87.48 billion, a price-to-earnings ratio of 15.79, a price-to-earnings-growth ratio of 1.35 and a beta of 1.68.

HCA Healthcare Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be paid a $0.66 dividend. This represents a $2.64 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Friday, December 13th. HCA Healthcare’s dividend payout ratio (DPR) is presently 11.85%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.